Umbilical cord mesenchymal stem cell-derived secretome as a potential treatment for systemic lupus erythematosus: A double-blind randomized controlled trial
Narra J · 2025
DOI: 10.52225/narra.v5i1.1799 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Narra J, 2025. Verfasst von Arief Nurudhin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Mesenchymal Stem Cells, Umbilical Cord, Secretome. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Umbilical cord mesenchymal stem cell-derived (UCMSC-derived) secretome is anti-apoptotic, anti-inflammatory, antifibrotic, angiogenic, and tissue-regenerating. Thus, it may treat systemic lupus erythematosus (SLE). The aim of this study was to investigate the impact of the UCMSC-derived secretome on SLE patients' disease activity, using Mexican systemic lupus erythematosus disease activity index (MEX-SLEDAI) score, complement (C3 and C4) levels, tumor necrosis factor-alpha (TNF-α), anti-double-stranded DNA (anti-dsDNA), and interleukin-6 (IL-6) levels. This double-blind randomized controlled trial investigated the efficacy and safety of UCMSC-derived secretome in SLE patients with moderate disease activity. A total of 29 female patients were randomized into two groups to receive weekly 1.5 cc intramuscular injections of UCMSC-derived secretome or placebo (0.9% NaCl) for six weeks. Disease activity was assessed using the MEX-SLEDAI score, C3 and C4 levels, pro-inflammatory cytokines (IL-6 and TNF-α), and anti-dsDNA antibodies at baseline, Day 22, and Day 43. Results showed a significant reduction in MEX-SLEDAI scores in the secretome group compared to the placebo group (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
- Division of Rheumatology, Department of Internal Medicine, Dr. Moewardi General Hospital, Surakarta, Indonesia.
- Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
- Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
- Department of Internal Medicine, Universitas Sebelas Maret Hospital, Surakarta, Indonesia.
- Department of Internal Medicine Program, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
Zitieren
APA
Nurudhin, A., Werdiningsih, Y., Sunarso, I., Marwanta, S., Damayani, A., Prabowo, N. A., Affandi, A., Gazali, I., Safitri, A. S., & Sidarta, B. R. (2025). Umbilical cord mesenchymal stem cell-derived secretome as a potential treatment for systemic lupus erythematosus: A double-blind randomized controlled trial. Narra J. https://doi.org/10.52225/narra.v5i1.1799
Vancouver
Nurudhin A, Werdiningsih Y, Sunarso I, Marwanta S, Damayani A, Prabowo NA, et al. Umbilical cord mesenchymal stem cell-derived secretome as a potential treatment for systemic lupus erythematosus: A double-blind randomized controlled trial. Narra J. 2025. doi:10.52225/narra.v5i1.1799
BibTeX
@article{Nurudhin2025,
author = {Nurudhin, Arief and Werdiningsih, Yulyani and Sunarso, Indrayana and Marwanta, Sri and Damayani, Aritantri and Prabowo, Nurhasan A and Affandi, Andri and Gazali, Itqan and Safitri, Ayu Si and Sidarta, Brigitte Ra},
title = {Umbilical cord mesenchymal stem cell-derived secretome as a potential treatment for systemic lupus erythematosus: A double-blind randomized controlled trial},
journal = {Narra J},
year = {2025},
doi = {10.52225/narra.v5i1.1799}
}
EUVIMED